Tell the FDA to Protect Access to EDTA Chelation!

Chelation is used by integrative physicians to remove heavy metals like lead, cadmium, and arsenic from the body. Doing so can clear up many, many health conditions (especially heart problems) and prevent worse ones from developing. The process involves injecting patients with organic chemicals—such as edetate disodium (EDTA), which is typically compounded—that bind and remove the heavy metals present in the bloodstream.

Unfortunately, the success of EDTA in reducing cardiovascular events could become a moot point if the FDA declares that it cannot be compounded, either making chelation almost completely unavailable or clearing the way for Big Pharma to patent an expensive chelation drug. Urge the FDA to preserve consumer access to EDTA chelation!

Please personalize and add your own
comments if you have time!

Recipients

Food and Drug Administration

Contact

*Required fields

* Title:

* First Name:

* Last Name:

* Your Email:

* Address 1:

Address 2:

* City:

* State / Province:

* ZIP / Postal Code:

Country:

* Phone Number:

Yes, I would like to receive periodic updates and communications from Alliance for Natural Health USA.

Remember me. What's this?

Message

Please Protect Access to Compounded EDTA Chelation

Dear [Decision Maker],

* Personalize your message

I know your agency is currently writing regulations for the Drug Quality and Security Act, and that you've been working on new rules for compounded medications. I'm writing to ask you to preserve consumer access to compounded EDTA chelation therapy.

Chelation is used by physicians to remove heavy metals like lead, cadmium, and arsenic from the body. Doing so can clear up many, many health conditions and prevent worse ones from developing. The process involves injecting patients with organic chemicals -- such as edetate disodium (EDTA), which is typically compounded -- that bind and remove the heavy metals present in the bloodstream.

Research has demonstrated that chelation is both safe and beneficial. The federally funded TACT (Trial to Assess Chelation Therapy) study, which included 1,708 patients across the US and Canada, showed that chelation reduced cardiovascular events in patients who were over 50 and had previously experienced a heart attack. The results of this randomized, double-blind study were even more profound for diabetic patients, who experienced a 43% reduction in death from cardiovascular events over five years.

Research based on the TACT trial also showed that concerns over the safety of EDTA were largely unwarranted. One study concluded: "The experience with 55,222 infusions of edetate disodium or placebo in TACT shows that this therapy is extremely safe when used according to the TACT safe infusion protocol."

Unfortunately, the success of EDTA in reducing cardiovascular events could become a moot point if your agency declares that it cannot be compounded, which would make chelation almost completely unavailable. Please protect and maintain consumer access to compounded EDTA chelation therapy -- it's safe, it's effective, and it's vital to the health of our citizens.

Sincerely,
[Your Name]
[Your Address]
[City, State ZIP]